Serum cell division cycle 42 in advanced hepatocellular carcinoma patients: Linkage with clinical characteristics and immune checkpoint inhibitor-related treatment outcomes - 11/08/23
Highlights |
• | This study enrolls advanced hepatocellular carcinoma patients taking immunotherapy. |
• | Cell division cycle 42 links with larger tumor size. |
• | Cell division cycle 42 links with reduced programmed death-ligand 1 expression. |
• | Cell division cycle 42 negatively links with disease control rate of immunotherapy. |
• | Cell division cycle 42 independently forecasts shorter progression-free survival. |
Abstract |
Objective |
Cell division cycle 42 (CDC42) facilitates immune escape and drug resistance towards immunotherapy in several malignancies. This prospective study aimed to explore the predictive value of serum CDC42 for immune checkpoint inhibitor (ICI)-treatment response and survival in advanced hepatocellular carcinoma (HCC) patients.
Methods |
Thirty advanced HCC patients scheduled for ICI or ICI-based treatment were enrolled in this prospective study, whose serum CDC42 was determined via enzyme-linked immunosorbent assay before therapy initiation.
Results |
The median (interquartile range) of serum CDC42 level was 766.5 (605.0–1329.5) pg/mL. Serum CDC42 was related to increased tumor size but decreased programmed death-ligand 1 combined positive score (PD-L1 CPS). With respect to ICI or ICI-based treatment outcomes, elevated serum CDC42 was associated with decreased disease control rate, but did not link with objective response rate. Patients with high serum CDC42 (vs. low, cut by its median level) had shortened progression-free survival (PFS), while overall survival (OS) only disclosed a reduced trend (lacked statistical significance) in patients with high serum CDC42 (vs. low). In detail, the median (95%CI) PFS and OS were 3.0 (0.0–6.0) months and 11.7 (2.7–20.7) months in patients with high serum CDC42, while they were 11.1 (6.6–15.6) months and 19.3 (14.5–24.1) months in patients with low CDC42. After adjusted by multivariate cox regression analysis, high serum CDC42 (vs. low) was independently associated with shortened PFS, but not OS.
Conclusions |
Elevated serum CDC42 possesses a potential value in predicting worse ICI or ICI-based treatment outcomes in advanced HCC.
Le texte complet de cet article est disponible en PDF.Keywords : Advanced hepatocellular carcinoma, Serum cell division cycle 42, Immune checkpoint inhibitor, Clinical characteristics, Treatment outcomes
Plan
Vol 47 - N° 7
Article 102149- août 2023 Retour au numéro
Article précédent
- The prognosis of elderly patients with hepatocellular carcinoma after curative hepatectomy a multicenter competing risk analysis
- Yi Lu, Lei Liang, Wen.Feng Lu, Jian Cheng, Wei.Feng Yao, Ya.Ming Xie, Dong.Dong Wang, Fei.Qi Xu, Zun.Qiang Xiao, Jun.Gang Zhang, Jun.Wei Liu, Cheng.Wu Zhang, Dong.Sheng Huang
- Fibrolamellar hepatocellular carcinoma: An epidemiologic and 5-year cancer survival assessment based off SEER data
- Mark M Aloysius, Peter Iskander, Khalid Ahmed, Udit Asija, Elmkdad Mohammed, Anthony Iskander, Niraj James Shah, Hemant Goyal, Vikas Khurana, Nasr Simin, Ganesh Aswath, Savio John
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?